
|Articles|March 4, 2014
- Vol 31 No 3
- Volume 31
- Issue 3
Data Point
Author(s)Richard M. Berlin, MD
Three years deep in despair, he’s swallowed every pill I prescribed...
Advertisement
While reviewing the results of a drug study for treatment-resistant depression
Three years deep in despair, he’s swallowed
every pill I prescribed. Refusing ECT,
his family and I convinced him to give
research medication one last shot.
Unblinded data arrived today and glows
on my computer screen, each depressed
patient’s response graphed with a dot,
the experimental molecule clearly beating
placebo, my patient’s outlier point six feet under
the rising line of success, a speck of coal
on a snow-covered field, my mind expanding
the insignificant dot to a skull’s eye socket
staring me down like a Beretta’s bullet hole.
Articles in this issue
over 12 years ago
The New CPT Codes: Ethical Challenges in a New Billing Era?over 12 years ago
End-of-Life Decisions: Who Decides and the Role of the Psychiatristover 12 years ago
Revive Flurothyl Inhalation Therapyover 12 years ago
Prescribing Psychotropics for Women of Childbearing Potentialover 12 years ago
Introduction: The Brave New World of Psychiatric Ethicsover 12 years ago
Ethics and Virtues in Clinical PsychiatryAdvertisement
Related to this article

A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.

Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.

Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.

How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Advertisement
Advertisement

